El interés en corto de Y-mAbs Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Y-mAbs Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Y-mAbs Therapeutics (NASDAQ:YMAB) Bolsa, Informe de interés en corto

Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Y-mAbs Therapeutics Inc

Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.04 by 250 percent. This is a 366.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $292.765 million which beat the analyst consensus estimate of $289.601 million by 1.09 percent. This is a 6.45 percent decrease over sales of $312.944 million the same period last year.

Earnings

Earnings Beats

News

FNKO

Funko Q3 2024 Adj. EPS $0.14 Beats $0.04 Estimate, Sales $292.765M Beat $289.601M Estimate

System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.29) by 17.24 percent. The company reported quarterly sales of $88.832 million which beat the analyst consensus estimate of $86.629 million by 2.54 percent. This is a 1.15 percent increase over sales of $87.818 million the same period last year.

Earnings Misses

System1 Q3 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $88.832M Beat $86.629M Estimate

Mexco Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) reported quarterly earnings of $0.15 per share. This is a 25 percent increase over earnings of $0.12 per share from the same period last year. The company reported $1.75 million in sales this quarter. This is a 24.32 percent increase over sales of $1.41 million the same period last year.

Mexco Energy Q2 EPS $0.15 Up From $0.12 YoY, Sales $1.75M Up From $1.41M YoY

WIIM

QDEL

QuidelOrtho shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue above estimates.

RXST

RxSight shares are trading lower. The company reported Q3 financial results.

EPRX

Eupraxia Pharmaceuticals Reports Q3 Net Income Of $(6.0)M, Down From $(4.9)M Loss Last Year

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 6.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $18.957 million which beat the analyst consensus estimate of $18.852 million by 0.56 percent. This is a 25.94 percent increase over sales of $15.052 million the same period last year.

TELA

TELA Bio Q3 2024 GAAP EPS $(0.42) Misses $(0.41) Estimate, Sales $18.957M Beat $18.852M Estimate

Tuscows Q3 Revenue $92.297M Up From 86.971M YoY

LCID

Lucid Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) .

Guidance

PBYI

Puma Biotechnology expects Q424 Net Product Revenue: $46M-$48M; FY2024: $187M-$190M (Prev. $183M-$190M).

KTOS

Kratos Defense & Security shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Offerings

Valley National Bancorp Announces Proposed Common Stock Offering

Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.08 by 112.5 percent. The company reported quarterly sales of $330.399 million which missed the analyst consensus estimate of $382.239 million by 13.56 percent. This is a 17.46 percent decrease over sales of $400.268 million the same period last year.

Bloom Energy Q3 2024 Adj. EPS $(0.01) Misses $0.08 Estimate, Sales $330.399M Miss $382.239M Estimate

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2025 GAAP EPS guidance from $6.15-6.35 to $6.15-6.35 vs $6.25 analyst estimate..

Chesapeake Utilities Affirms FY2025 GAAP EPS Guidance from $6.15-6.35 to $6.15-6.35 vs $6.25 Est

CPRI

Capri Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2024 GAAP EPS guidance from $5.33-5.45 to $5.33-5.45 vs $5.39 analyst estimate..

Chesapeake Utilities Affirms FY2024 GAAP EPS Guidance from $5.33-5.45 to $5.33-5.45 vs $5.39 Est

Buybacks

TRIN

Trinity Capital Inc. Announces Stock Repurchase Program Of Up To $30M

FLYW

Flywire shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 18.37 percent increase over losses of $(0.49) per share from the same period last year.

Vor Biopharma Q3 EPS $(0.40), Inline

Ovintiv Sees FY24 Capital Investment $2.275B-$2.325B

In a report released today, Nicole Germino from Truist Financial reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report), with a pr...

Truist Financial Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)

Y-Mabs Therapeutics (YMAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout...

Buy Rating Affirmed for Y-Mabs Therapeutics Amid Solid R&D Prospects and Resilient Financial Performance

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report) and Y-Mabs Therapeutics (YMAB – R...

Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Y-Mabs Therapeutics (YMAB – Research Report), Resm...

Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) and Bayer (GB:0P6S)

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (YMAB – Research Report), with a price ...

Morgan Stanley Remains a Sell on Y-Mabs Therapeutics (YMAB)

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)

JonesTrading analyst Justin Walsh has reiterated their bullish stance on YMAB stock, giving a Buy rating today. Justin Walsh's rating is based on s...

Optimistic Buy Rating for Y-Mabs Therapeutics Driven by Innovative SADA PRIT Technology and Strategic Advancements

Y-mAbs and Nobelpharma sign license and distribution agreement for DANYELZA in Japan

The latest update is out from Y-Mabs Therapeutics ( ($YMAB) ). Y-mAbs Therapeutics has signed an exclusive agreement with Nobelpharma to develop an...

Y-mAbs Partners with Nobelpharma for Japan Expansion

TLRY

YMAB

Management

Press Releases

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Legal

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs to Participate in Upcoming Investor Conferences in September

Health Care

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Comments

Y-mAbs Therapeutics

Interés en corto

Y-mAbs Therapeutics (NASDAQ:YMAB) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL